Skadden is advising Revance Therapeutics, while Kirkland & Ellis and Lowenstein Sandler are advising Crown Laboratories on the deal. Crown Laboratories, Inc., a privately held, global...
You must be a Standard 1 Year member to access this content.
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented the sales agents in the offering. Meta Materials Inc. announced its At-The-Market sales agreement for the issuance of up to $100 million of...
You must be a Standard 1 Year member to access this content.
Lowenstein represented BTIG, LLC, Oppenheimer & Co. Inc., and B. Riley Securities, Inc. as sales agents in the offering. Celularity, Inc. executed an at-the-market offering of up...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Crown Laboratories in the transaction. Crown Laboratories, Inc. (“Crown”), a leading, fully integrated global skincare company, announced its agreement with Eclipse MedCorp LLC,...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Celldex Therapeutics in the offering. Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) executed its $287.5 million public offering of common stock. Jefferies, SVB Leerink,...
You must be a Standard 1 Year member to access this content.
